Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
종목 코드 ETON
회사 이름Eton Pharmaceuticals Inc
상장일Nov 09, 2018
CEOMr. Sean E. Brynjelsen
직원 수31
유형Ordinary Share
회계 연도 종료Nov 09
주소21925 W Field Pkwy Ste 235
도시DEER PARK
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호60010-7278
전화18477877361
웹사이트https://etonpharma.com/
종목 코드 ETON
상장일Nov 09, 2018
CEOMr. Sean E. Brynjelsen
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음